Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase NA 4Phase 2 4Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 4INDUSTRY 3OTHER_GOV 1OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 4Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Polycystic Ovary Syndrome 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Weight Loss 1Warts 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Oesophagogastric Cancer 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lung Neoplasms 1Leukopenia 1Leukemia, Promyelocytic, Acute 1Leukemia, Biphenotypic, Acute 1Insulin Resistance 1Infertility 1Immunotherapy Gastrict Cancer 1Hydatidiform Mole 1Glioma 1

Interventions

Poly(ADP-ribose) Polymerase Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER_GOV × Fallopian Tube Neoplasms × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡